Date: 2025/05/19 - 22:32
Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly. Participants who received tirzepatide also had greater improvements in metabolic risk factors. Tirzepatide's dual effects on GLP-1 and GIP may explain its superior performance.